These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 21715576)

  • 21. Structure and function of a malaria transmission blocking vaccine targeting Pfs230 and Pfs230-Pfs48/45 proteins.
    Singh K; Burkhardt M; Nakuchima S; Herrera R; Muratova O; Gittis AG; Kelnhofer E; Reiter K; Smelkinson M; Veltri D; Swihart BJ; Shimp R; Nguyen V; Zhang B; MacDonald NJ; Duffy PE; Garboczi DN; Narum DL
    Commun Biol; 2020 Jul; 3(1):395. PubMed ID: 32709983
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Transmission-blocking immunity to Plasmodium falciparum in malaria-immune individuals is associated with antibodies to the gamete surface protein Pfs230.
    Healer J; McGuinness D; Carter R; Riley E
    Parasitology; 1999 Nov; 119 ( Pt 5)():425-33. PubMed ID: 10599074
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cell-traversal protein for ookinetes and sporozoites (CelTOS) formulated with potent TLR adjuvants induces high-affinity antibodies that inhibit Plasmodium falciparum infection in Anopheles stephensi.
    Pirahmadi S; Zakeri S; A Mehrizi A; D Djadid N; Raz AA; J Sani J; Abbasi R; Ghorbanzadeh Z
    Malar J; 2019 Apr; 18(1):146. PubMed ID: 31014347
    [TBL] [Abstract][Full Text] [Related]  

  • 24. ELISA units, IgG subclass ratio and avidity determined functional activity of mouse anti-Pfs230 antibodies judged by a standard membrane-feeding assay with Plasmodium falciparum.
    Miura K; Deng B; Wu Y; Zhou L; Pham TP; Diouf A; Wu CK; Lee SM; Plieskatt JL; Morin MJ; Long CA
    Vaccine; 2019 Apr; 37(15):2073-2078. PubMed ID: 30850239
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Functional Characterization and Comparison of
    Nikolaeva D; Illingworth JJ; Miura K; Alanine DGW; Brian IJ; Li Y; Fyfe AJ; Da DF; Cohuet A; Long CA; Draper SJ; Biswas S
    Mol Cell Proteomics; 2020 Jan; 19(1):155-166. PubMed ID: 29089373
    [No Abstract]   [Full Text] [Related]  

  • 26. The Pfs230 N-terminal fragment, Pfs230D1+: expression and characterization of a potential malaria transmission-blocking vaccine candidate.
    Lee SM; Wu Y; Hickey JM; Miura K; Whitaker N; Joshi SB; Volkin DB; Richter King C; Plieskatt J
    Malar J; 2019 Nov; 18(1):356. PubMed ID: 31703583
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Improving the malaria transmission-blocking activity of a Plasmodium falciparum 48/45 based vaccine antigen by SpyTag/SpyCatcher mediated virus-like display.
    Singh SK; Thrane S; Janitzek CM; Nielsen MA; Theander TG; Theisen M; Salanti A; Sander AF
    Vaccine; 2017 Jun; 35(30):3726-3732. PubMed ID: 28578824
    [TBL] [Abstract][Full Text] [Related]  

  • 28. In vitro studies with recombinant Plasmodium falciparum apical membrane antigen 1 (AMA1): production and activity of an AMA1 vaccine and generation of a multiallelic response.
    Kennedy MC; Wang J; Zhang Y; Miles AP; Chitsaz F; Saul A; Long CA; Miller LH; Stowers AW
    Infect Immun; 2002 Dec; 70(12):6948-60. PubMed ID: 12438374
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Antibody responses to two new Lactococcus lactis-produced recombinant Pfs48/45 and Pfs230 proteins increase with age in malaria patients living in the Central Region of Ghana.
    Acquah FK; Obboh EK; Asare K; Boampong JN; Nuvor SV; Singh SK; Theisen M; Williamson KC; Amoah LE
    Malar J; 2017 Aug; 16(1):306. PubMed ID: 28764709
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Surface antigens of Plasmodium falciparum gametocytes--a new class of transmission-blocking vaccine targets?
    Sutherland CJ
    Mol Biochem Parasitol; 2009 Aug; 166(2):93-8. PubMed ID: 19450726
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Identification of Plasmodium falciparum reticulocyte binding protein homologue 5-interacting protein, PfRipr, as a highly conserved blood-stage malaria vaccine candidate.
    Ntege EH; Arisue N; Ito D; Hasegawa T; Palacpac NMQ; Egwang TG; Horii T; Takashima E; Tsuboi T
    Vaccine; 2016 Nov; 34(46):5612-5622. PubMed ID: 27692771
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Murine model for assessment of Plasmodium falciparum transmission-blocking vaccine using transgenic Plasmodium berghei parasites expressing the target antigen Pfs25.
    Mlambo G; Maciel J; Kumar N
    Infect Immun; 2008 May; 76(5):2018-24. PubMed ID: 18316385
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Structural vaccinology of malaria transmission-blocking vaccines.
    Patel PN; Tolia N
    Expert Rev Vaccines; 2021 Feb; 20(2):199-214. PubMed ID: 33430656
    [No Abstract]   [Full Text] [Related]  

  • 34. Functional immunogenicity of baculovirus expressing Pfs25, a human malaria transmission-blocking vaccine candidate antigen.
    Mlambo G; Kumar N; Yoshida S
    Vaccine; 2010 Oct; 28(43):7025-9. PubMed ID: 20709008
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Immunogenicity of a chimeric Plasmodium falciparum merozoite surface protein vaccine in Aotus monkeys.
    Burns JM; Miura K; Sullivan J; Long CA; Barnwell JW
    Malar J; 2016 Mar; 15():159. PubMed ID: 26975721
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A multi-stage malaria vaccine candidate targeting both transmission and asexual parasite life-cycle stages.
    Theisen M; Roeffen W; Singh SK; Andersen G; Amoah L; van de Vegte-Bolmer M; Arens T; Tiendrebeogo RW; Jones S; Bousema T; Adu B; Dziegiel MH; Christiansen M; Sauerwein R
    Vaccine; 2014 May; 32(22):2623-30. PubMed ID: 24662702
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The antibody response to Plasmodium falciparum Merozoite Surface Protein 4: comparative assessment of specificity and growth inhibitory antibody activity to infection-acquired and immunization-induced epitopes.
    de Silva HD; Saleh S; Kovacevic S; Wang L; Black CG; Plebanski M; Coppel RL
    Malar J; 2011 Sep; 10():266. PubMed ID: 21920045
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pfs230 yields higher malaria transmission-blocking vaccine activity than Pfs25 in humans but not mice.
    Healy SA; Anderson C; Swihart BJ; Mwakingwe A; Gabriel EE; Decederfelt H; Hobbs CV; Rausch KM; Zhu D; Muratova O; Herrera R; Scaria PV; MacDonald NJ; Lambert LE; Zaidi I; Coelho CH; Renn JP; Wu Y; Narum DL; Duffy PE
    J Clin Invest; 2021 Apr; 131(7):. PubMed ID: 33561016
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Expression, Purification and Characterization of GMZ2'.10C, a Complex Disulphide-Bonded Fusion Protein Vaccine Candidate against the Asexual and Sexual Life-Stages of the Malaria-Causing Plasmodium falciparum Parasite.
    Mistarz UH; Singh SK; Nguyen TTTN; Roeffen W; Yang F; Lissau C; Madsen SM; Vrang A; Tiendrebeogo RW; Kana IH; Sauerwein RW; Theisen M; Rand KD
    Pharm Res; 2017 Sep; 34(9):1970-1983. PubMed ID: 28646324
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Immunogenicity of a recombinant malaria vaccine candidate, domain I+II of AMA-1 ectodomain, from Indian P. falciparum alleles.
    Lalitha PV; Biswas S; Pillai CR; Saxena RK
    Vaccine; 2008 Aug; 26(35):4526-35. PubMed ID: 18590786
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.